As an email insider, youll get wellness tips with GLP-1 support in mind, a first look at new product launches, expert insights and more
Thats just one example and Sage Growth Partners research shows that virtual health assistants are among the top use cases in place today, while healthcare C-suites are also investing in or exploring AI for health behavior modification
L.DenkelK.et al (2023)
A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinsons disease
In November 2024, Novo Nordisk AS is expected to secure expanded FDA approval for CagriSema, its dual amylin/GLP-1 agonist, for a broader population of patients with type 2 diabetes and high cardiovascular risk
Your optimal choice depends entirely on your medical history, your budget, and your long-term goals